Provider Attitudes and Practices for Alcohol Screening, Treatment, and Education in Patients With Liver Disease: A Survey From the American Association for the Study of Liver Diseases Alcohol-Associated Liver Disease Special Interest GroupGene Y. Im, Vijay H. Shah, Zurabi Lominadze et al.|Clinical Gastroenterology and Hepatology|2020Cited by 112
Durability of treatment response after 1 year of therapy with seladelpar in patients with primary biliary cholangitis (PBC): final results of an international phase 2 studyCynthia Levy, Alexandra Steinberg, Ke Yang et al.|Journal of Hepatology|2020Cited by 10
Su1348: EFFICACY, SAFETY, AND TOLERABILITY OF SELADELPAR IN PATIENTS WITH COMPENSATED LIVER CIRRHOSIS DUE TO PRIMARY BILIARY CHOLANGITIS (PBC); A POOLED ANALYSIS OF PHASE 2 AND PHASE 3 STUDIESStuart C. Gordon, Marlyn J. Mayo, Ke Yang et al.|Gastroenterology|2022Cited by 2
686 EFFECTS ON PRURITUS AND SLEEP DISTURBANCE IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AFTER 1 YEAR OF TREATMENT WITH SELADELPAR, A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR DELTA AGONIST: RESULTS OF AN OPEN-LABEL PHASE 2 STUDYAndreas E. Kremer, Yun‐Jung Choi, Christopher L. Bowlus et al.|Gastroenterology|2020Cited by 1
Medications for Weight Loss and MASLDGene Y. Im, Meena B. Bansal, Amon Asgharpour et al.|Journal of Clinical Gastroenterology|2025Cited by 1